Manufacturing Daily Summary
Manufacturing Daily Summary: What Happened on October 12, 2026
GSK commits more than $800 million to Pennsylvania expansion
A UK report warns that rising immunoglobulin demand and import reliance could strain supply.
-
P
Today in brief
GSK plans to spend more than $800 million expanding manufacturing and research at its Upper Merion, Pennsylvania, site.1 A report funded by argenx says imports account for about 80% of UK immunoglobulin supply, while demand keeps rising.2
GSK plans new manufacturing and research facilities in Pennsylvania
GSK plans to invest more than $800 million in its Upper Merion operations and build facilities for clinical and commercial supply.1 The planned hub includes a biologics production site, an R&D pilot plant, a quality control laboratory, and a manufacturing science and technology hub.1
GSK plans to start removing existing buildings next year.1 Pennsylvania officials expect the project to create more than 300 jobs over five years and retain about 4,500 existing GSK positions in the state.1
Also worth knowing
-
P
The Office of Health Economics report puts UK plasma collection at about 4.4 liters per 1,000 people, versus a European average of 14 liters. NHS Blood and Transplant targets 30–35% plasma self-sufficiency by 2030.2
Also published
- Trio become latest Symbiosis commercial additions Pharmafile
- The Manufacturing Issues That Continue to Contribute to Drug Shortages Pharmaceutical Executive
- Perfusion for next generation biosimilars European Biotechnology
- Every process is different. Not the platform. European Biotechnology